Why Is Halozyme Therapeutics (HALO) Down 13.1% Since Last Earnings Report?Zacks Investment Research • 03/19/26
Halozyme Therapeutics, Inc. (HALO) Presents at The Citizens Life Sciences Conference 2026 TranscriptSeeking Alpha • 03/11/26
Halozyme Therapeutics, Inc. (HALO) Presents at Leerink Global Healthcare Conference 2026 TranscriptSeeking Alpha • 03/10/26
U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple MyelomaPRNewsWire • 03/06/26
Halozyme Therapeutics, Inc. (HALO) Presents at TD Cowen 46th Annual Health Care Conference TranscriptSeeking Alpha • 03/04/26
Here's What Key Metrics Tell Us About Halozyme Therapeutics (HALO) Q4 EarningsZacks Investment Research • 02/18/26
Halozyme Therapeutics (HALO) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 02/17/26
HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCEPRNewsWire • 02/17/26
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum StockZacks Investment Research • 02/16/26
Stay Ahead of the Game With Halozyme Therapeutics (HALO) Q4 Earnings: Wall Street's Insights on Key MetricsZacks Investment Research • 02/13/26
Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating ResultsPRNewsWire • 02/10/26
Halozyme Therapeutics (HALO) to Report Q4 Results: Wall Street Expects Earnings GrowthZacks Investment Research • 02/10/26
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-TermZacks Investment Research • 02/04/26
5 Stocks To Watch Trade Near Buy Points; Three Are Data Center PlaysInvestors Business Daily • 01/31/26
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-TermZacks Investment Research • 01/30/26
HALO Rises Nearly 4% on Strong 2025 Preliminary Data and 2026 GuidanceZacks Investment Research • 01/29/26
Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial GuidancePRNewsWire • 01/28/26